FDA accepts AstraZeneca's fish oil-based drug Epanova for review

09/19/2013 | Reuters · PharmaTimes (U.K.)

The FDA has accepted AstraZeneca's application to market its fish oil-based drug Epanova as a treatment for severe hypertriglyceridemia. The drug was originally developed by Omthera Pharmaceuticals, which was bought by AstraZeneca this year. A decision is expected by May 5.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT